Nkarta Therapeutics

Nkarta Therapeutics is a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer.

Nkarta Therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.

Nkarta was founded on the proprietary, robust and well characterized natural killer (NK) cell expansion technology pioneered by Dario Campana in 2015. The company is based in San Francisco, California.

Nkarta is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable.

Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer.

 

Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer.

 

Nkarta's investors inclue NEA Ventures, Novo Holdings A/S, Samsara BioCapital, Amgen Ventures, Deerfield Management, Life Science Partners, Logos Capital, & SR One among others. The company raised $114M in its latest funding of a "Series B" round on Sep 4, 2019. This brings Nkarta's total funding to $125M to-date.

 

 

  • Year founded: 2015
  • Funding Info: $125M in 2 Funding Rounds (Last Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: San Francisco
  • State: California
  • Country: United States
Related businesses